Monitoring requirements Consultant Clause Samples

The 'Monitoring requirements Consultant' clause defines the consultant's obligations to oversee and report on specific aspects of a project or service. Typically, this clause outlines the frequency and format of monitoring activities, such as regular site visits, progress reports, or compliance checks, and may specify the standards or metrics to be used. Its core practical function is to ensure that the consultant actively tracks project performance and compliance, providing transparency and accountability to the client throughout the engagement.
Monitoring requirements Consultant specialist responsibilities Best practice recommends the following precautions for specialists before commencing immunosuppressant therapy: • Record patient’s blood pressure, weight and height if clinically indicated. • Screening for lung disease should be undertaken at clinician discretion on a case- by-case basis. The extent of screening should be influenced more by a patient’s clinical features and risk factors for lung disease (e.g. underlying autoimmune disease or smoking history) rather than subsequent immunomodulating choice. Pre-existing lung disease should not be considered an absolute contraindication to any immunomodulating medication. • Consultant to consider ECG where appropriate especially when commencing medications associated with hypertension • Screen for viral hepatitis B&C and HIV in all patients • Investigate patient medical history including co-morbidities and previous immunomodulating medication use. For rheumatic patients CRP/ESR may be done every 3 months. These tests are part of the assessment of the underlying rheumatic disease rather than a requirement for monitoring of immunomodulating therapy. The monitoring CRP/ESR may be coordinated between secondary and primary care on an individual basis. Pregnancy must be excluded before starting treatment Consultant/specialist monitoring schedule Baseline and 2 weekly until on a stable dose for at least 6 weeks • FBC • ALT and/or AST and albumin • U&E including creatinine/calculated GFR • Blood pressure • Patient is asked to report any unexplained weight loss (>10%) Annually review the patient and advise the GP promptly on when to adjust the dose, stop treatment or consult with the specialist. GP responsibility monitoring schedule In patients following the 6 weeks of dose stability conduct monthly monitoring as above for three months followed by three monthly monitoring thereafter of: • FBC • ALT and/or AST and albumin • U&E including creatinine/eGFR • Blood pressure • Patient asked to report any unexplained weight loss (>10%) See advice below on pregnancy and breastfeeding in section (Caution and contraindication) Leflunomide in combination with MTX requires extended monthly monitoring for at least 12 months. Patients who have been stable for 12 months can be considered for reduced frequency of monitoring on an individual patient basis. Dosage increase For dose increase, monitor 2 weekly until stable for 6 weeks. Dose and monitoring to be agreed with consultant. • FBC • ALT and/or AST an...
View SourceView Similar (2)
Monitoring requirements Consultant specialist monitoring schedule Baseline and 2 weekly until on a stable dose for at least 6 weeks • FBC • ALT and/or AST and albumin • U&E including creatinine/calculated GFR • Urinalysis Periodically review the patient and advise the GP promptly on when to adjust the dose, stop treatment or consult with the specialist. In patients following the 6 weeks of dose stability conduct monthly monitoring: • FBC • ALT and/or AST and albumin • U&E including creatinine/ calculated GFR • urinalysis (blood and protein) Patient should be asked about the presence of rash or oral ulceration at each visit. For patients with inflammatory arthritis CRP/ESR may be done every 3 months
View SourceView Similar (2)
Monitoring requirements Consultant specialist monitoring schedule Baseline and 2 weekly until on a stable dose for at least 6 weeks • FBC • ALT and/or AST and albumin • U&E including creatinine/CrCl • Urinalysis Periodically review the patient and advise the GP promptly on when to adjust the dose, stop treatment or consult with the specialist. GP responsibility monitoring schedule In patients following the 6 weeks of dose stability conduct monthly monitoring: • FBC • ALT and/or AST and albumin • U&E including creatinine/ CrCl • urinalysis (blood and protein) Patients who have been stable for 12 months can be considered for reduced monitoring frequency (every 3 months) on an individual basis. Patient should be asked about the presence of rash or oral ulceration at each visit. For rheumatic patients CRP/ESR may be done every 3 months (this is not done for dermatology patients). These tests are part of the assessment of the underlying rheumatic disease rather than a requirement for monitoring of immunomodulating therapy. The monitoring CRP/ESR may be coordinated between secondary and primary care on an individual basis. Patients with Renal impairment- Fortnightly monitoring throughout treatment for rheumatoid arthritis.
View Source

Related to Monitoring requirements Consultant

  • Monitoring Requirements This Schedule sets out the contract management requirements which are applicable to the delivery of the Services.

  • Training Requirements Grantee will: A. Authorize and require staff (including volunteers) to attend training, conferences, and meetings as directed by DSHS. B. Appropriately budget funds to meet training requirements in a timely manner, and ensure staff and volunteers are trained as specified in the training requirements listed at ▇▇▇▇▇://▇▇▇.▇▇▇▇.▇▇▇▇▇.▇▇▇/hivstd/training/ and as otherwise specified by DSHS. Grantee shall document that these training requirements are met. C. Follow the appropriate DSHS POPS by funding opportunity (as per Section I: General Requirements for All Grantees) for training and observation requirements.

  • Screening Requirements LFAC shall ensure that all prospective and current Covered Persons are not Ineligible Persons, by implementing the following screening requirements. a. LFAC shall screen all prospective Covered Persons against the Exclusion List prior to engaging their services and, as part of the hiring or contracting process, shall require such Covered Persons to disclose whether they are Ineligible Persons. b. LFAC shall screen all current Covered Persons against the Exclusion List within 30 days after the Effective Date and on a monthly basis thereafter. c. LFAC shall require all Covered Persons to disclose immediately if they become an Ineligible Person. LFAC shall maintain documentation (i.e., a print screen of the search results) in order to demonstrate that LFAC: (1) has checked the Exclusion List and determined that its Covered Persons are not Ineligible Persons; and (2) has required its Covered Persons to disclose if they are an Ineligible Person. Nothing in this Section III.D affects LFAC’s responsibility to refrain from (and liability for) billing Federal health care programs for items or services furnished, ordered, or prescribed by an excluded person. LFAC understands that items or services furnished by excluded persons are not payable by Federal health care programs and that LFAC may be liable for overpayments and/or criminal, civil, and administrative sanctions for employing or contracting with an excluded person regardless of whether LFAC meets the requirements of Section III.D.

  • Staffing Requirements Licensee will be in full compliance with the main studio staff requirements as specified by the FCC.

  • Testing Requirements 12.1. Workplaces - 12.2. On workplaces where the value of the Commonwealth’s contribution to the project that includes the building work is at least $5,000,000, and represents at least 50% of the total construction project value or the Commonwealth’s contribution to the project that includes the building work is at least $10,000,000 (irrespective of its proportion of the total construction project value) the following minimum testing requirements must be adhered to.